Prokidney PROK
NASDAQ PROK
$1.85 -0.14 (-7.04%)
At close: Sep 9, 2026 · 4:00 PM EDT

Prokidney (PROK) Long-Term Deferred Tax (2022 - 2023)

Prokidney's (PROK) quarterly Long-Term Deferred Tax came in at $1.5 million in Q4 2023, down 15.12% year-over-year from $1.8 million in Q4 2022, and down 15.12% quarter-over-quarter from $1.8 million in Q4 2022.

Analysis

Prokidney (PROK) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends

Prokidney (PROK) has reported Long-Term Deferred Tax for 2 consecutive years, with $1.5 million the latest figure, recorded in Q4 2023.

  • On a quarterly basis, Long-Term Deferred Tax fell 15.12% year-over-year to $1.5 million in Q4 2023; TTM through Dec 2023 was $1.5 million, a 15.12% decrease from a year earlier, with the FY2023 full-year figure at $1.5 million, down 15.12% from the prior year.
  • Long-Term Deferred Tax was $1.5 million for Q4 2023 at Prokidney, down from $1.8 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $1.8 million in Q4 2022 and troughed at $1.5 million in Q4 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Krystal Biotech 10.27 Bn 9.43 Bn 112.79 Mn
2 CRISPR Therapeutics AG 5.17 Bn 5.17 Bn -
3 Iovance Biotherapeutics 3.79 Bn 3.49 Bn 55.72 Mn
4 Legend Biotech 3.68 Bn 2.71 Bn 251.50 Mn
5 uniQure 3.05 Bn 3.05 Bn 5.49 Mn
6 Beam Therapeutics 2.65 Bn 2.65 Bn -
7 Precigen 2.44 Bn 2.44 Bn 52.17 Mn
8 Sarepta Therapeutics 2.33 Bn 1.53 Bn 251.87 Mn
9 Vericel 1.99 Bn 1.83 Bn 56.40 Mn
10 Prokidney 346.07 Mn 346.07 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 1.49 Mn
Dec 31, 2022 1.76 Mn